Commissioner Califf: Cardiologist, Clinical Trials Expert Ascends At FDA
This article was originally published in The Gray Sheet
Executive Summary
The Senate confirmed Robert Califf as the new FDA commissioner after months of delay, giving the cardiologist, clinical trial expert and established agency official a better platform to push his priorities, which include combination product and clinical data-collection reforms, while implementing projects already under way.
You may also be interested in...
Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?
Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.
FDA's Califf Seeks His First Big Hire: Chief Scientist
The US agency seeks candidates for the executive position in charge of its research policy apparatus.
FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.